Pennsylvania Elmiron Pigmentary Maculopathy injury lawyer
We represent Pennsylvania residents who have suffered vision loss or permanent eye damage after taking Elmiron (pentosan polysulfate sodium) for interstitial cystitis. For years, patients trusted this medication to manage a painful bladder condition, unaware that long-term use could silently destroy the retina. By 2026, the legal and medical landscape has shifted dramatically: thousands of lawsuits have been consolidated in multidistrict litigation (MDL), and the FDA has mandated stronger warning labels. If you or a loved one took Elmiron for more than a year and now experience blurred vision, difficulty reading, or dark spots in your field of view, you may have a claim for pigmentary maculopathy.
Our firm focuses exclusively on Pennsylvania Elmiron injury cases. We have reviewed hundreds of medical records, consulted with retinal specialists at Wills Eye Hospital in Philadelphia, and tracked every development in the federal MDL before Judge Brian R. Martinotti in New Jersey. The science is clear: chronic Elmiron exposure causes a distinct pattern of retinal toxicity that mimics age-related macular degeneration but strikes younger patients. We are here to help you navigate the complex intersection of pharmaceutical liability, medical causation, and Pennsylvania’s statute of limitations.
How Elmiron Damages the Retina: The Wills Eye Hospital Studies That Changed Everything
The first major alarm sounded in 2018 when researchers at Wills Eye Hospital in Philadelphia published a case series linking Elmiron to pigmentary maculopathy. Dr. Nieraj Jain and his team identified a pattern of retinal pigment epithelium (RPE) changes in patients who had taken the drug for years. Since then, dozens of peer-reviewed studies have confirmed the link, including a 2022 meta-analysis showing that the risk rises with cumulative dosage. The FDA updated the prescribing information in 2020 and again in 2023, but many patients—and even some ophthalmologists—remain unaware of the connection.
“The latency period between starting Elmiron and developing maculopathy can be five to fifteen years. By the time symptoms appear, the damage is often irreversible. Pennsylvania patients who took the drug before 2020 may still be developing symptoms today. We urge anyone with a history of Elmiron use and vision changes to schedule a dilated retinal exam immediately.” — Our team, drawing on findings from f1000prime.com and archived reference materials.
We have compiled key data from the leading studies to help you understand the scope of the problem:
| Study / Institution | Year | Number of Patients | Key Finding |
|---|---|---|---|
| Wills Eye Hospital (Jain et al.) | 2018 | 6 | First case series linking Elmiron to maculopathy |
| Emory University (Pearce et al.) | 2020 | 35 | Confirmed dose-dependent retinal toxicity |
| Kaiser Permanente (Lorenz et al.) | 2022 | 140 | 15% of long-term users showed retinal changes |
| FDA Adverse Event Reporting System | 2023 | 1,200+ | Updated label to include “pigmentary maculopathy” warning |
Janssen Pharmaceuticals and the MDL: What Pennsylvania Plaintiffs Face in 2026
Elmiron is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. As of early 2026, the multidistrict litigation (MDL No. 2973) in the District of New Jersey includes over 2,500 active cases. Bellwether trials have yielded mixed results: two plaintiff verdicts, one defense verdict, and several settlements. Pennsylvania plaintiffs are well-positioned because our state’s product liability law follows the “risk-utility” test, which allows juries to weigh the drug’s benefits against its undisclosed dangers. We have successfully argued that Janssen knew about the retinal risks as early as 2015 but failed to warn doctors or patients until after the Wills Eye publication.
Key steps for Pennsylvania residents considering a lawsuit:
- Confirm your Elmiron history: Check pharmacy records, prescription bottles, or medical charts for the drug name and dosage. We can subpoena records if needed.
- Obtain a retinal exam: An optical coherence tomography (OCT) scan and fundus autofluorescence imaging can document maculopathy. We work with retina specialists across Pennsylvania, including Pittsburgh, Harrisburg, and Allentown.
- Preserve evidence: Do not discard old pill bottles or pharmacy receipts. The date of first use is critical for statute of limitations calculations.
- Contact us before the deadline: Pennsylvania’s two-year statute of limitations runs from the date you discovered (or should have discovered) the injury. For many, that clock started ticking only after a 2020 or 2023 diagnosis.
Why Pennsylvania’s Medical Community Still Misses Elmiron Maculopathy
Despite the mounting evidence, many general ophthalmologists and optometrists in Pennsylvania do not routinely ask patients about Elmiron use. The drug is prescribed primarily by urologists for interstitial cystitis, a condition that disproportionately affects women. When these patients complain of vision changes, their eye doctor may attribute it to dry eye, cataracts, or age-related changes—especially if the patient is over 50. We have seen cases where patients saw three or four eye specialists before anyone connected the dots to Elmiron. This diagnostic delay is precisely why we advocate for mandatory screening protocols in every urology and ophthalmology practice across the state.
If you have been told you have “macular degeneration” but are under 60 and have a history of bladder medication, ask your doctor specifically about Elmiron pigmentary maculopathy. The treatment is immediate discontinuation of the drug, and while vision loss is often permanent, early detection can prevent further deterioration. Our firm offers free case evaluations to Pennsylvania residents, and we handle all litigation on a contingency basis—you pay nothing unless we recover compensation for you.